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Abstract
Background: Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis
characterized by entry of activated T cells and antigen presenting cells into the central nervous system and
subsequent autoimmune destruction of nerve myelin. Previous studies revealed that non-selective inhibition of poly
(ADP-ribose) polymerases (PARPs) 1 and 2 protect against neuroinflammation and motor dysfunction associated
with EAE, but the role of the PARP-2 isoform has not yet been investigated selectively.
Results: EAE was induced in mice lacking PARP-2, and neurological EAE signs, blood-spine barrier (BSB)
permeability, demyelination and inflammatory infiltration were monitored for 35 days after immunization. Mice
lacking PARP-2 exhibited significantly reduced overall disease burden and peak neurological dysfunction. PARP-2
deletion also significantly delayed EAE onset and reduced BSB permeability, demyelination and central nervous
system (CNS) markers of proinflammatory Th1 and Th17 T helper lymphocytes.
Conclusions: This study represents the first description of a significant role for PARP-2 in neuroinflammation and
neurological dysfunction in EAE.
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Introduction
Multiple sclerosis (MS) affects up to 1% of the US popu-
lation and 2% of Canadians [1,2], and is characterized by
central nervous system (CNS) lymphocyte infiltration, auto-
immune demyelination, axonal loss and neurodegeneration
[3,4]. Experimental allergic encephalomyelitis (EAE) is an
animal model that shares many features with human MS,
including major histocompatibility complex (MHC)-linked
susceptibility, female predominance, paralysis, ataxia,
increased cytokine production, and the presence of myelin-
reactive T cells [5].
Poly(ADP-ribose) polymerases (PARPs) comprise a
superfamily of 18 enzymes involved in DNA repair and
genomic stability [6,7]. PARP-1 and PARP-2 share the abil-
ity to catalyze poly ADP-ribosylation of target proteins [8]
but PARP-1 accounts for about 90% of cellular poly
ADP-ribosylation capacity [7,9]. Non-selective PARP-1/2
inhibitors reduce neuroinflammation and neurological
dysfunction in rodent EAE [10-12] but it is not yet clear
what the relative contributions of PARP-1 and PARP-2 are
to this effect. Genetic PARP-1 loss of function in EAE has
produced disparate results, both mitigating [13] and en-
hancing [14] EAE severity in mice. Our aim in the present
work was to evaluate the role of PARP-2 deletion in EAE.
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Methods
All animal experiments were performed in accordance
with guidelines of and approved by the Institutional
Animal Care and Use Committee, University of Manitoba.
EAE was induced in 8-week-old parp-2−/− female mice [9]
or wild-type littermate C57Bl/6 controls by immunizing
with myelin oligodendrocyte glycoprotein (MOG)35–55
and Freund’s complete adjuvant (FCA) [15]. Two subcuta-
neous injections with 50 μg of MOG35-55 emulsified in
FCA containing 200 μg of Mycobacterium tuberculosis
were given on day 0 and 7 days after. Mice also received
intraperitoneal pertussis toxin (0.15 μg in 100 μl
phosphate-buffered saline (PBS)) on day 0 and day 2.
Body weight and neurological score were measured
daily. Mice were assigned a cumulative 14-point score
[16], assessing function of tail and mobility of each
front limb and each hind limb, up to 35 days after the
second immunization. For tail function, a score of 0 is
asymptomatic, while 1 refers to weakness and 2 is
full paralysis. For the hind or forelimbs, each is assessed
separately, with a score of 0 for no symptoms, 1 for
weakness, 2 for limb dragging with limited movement,
and 3 for full paralysis.
Permeability of the blood-spine barrier was deter-
mined at initiation of disease signs, as tracked by loss
of >1 g of body mass [17], by injecting mice with 100 μl
of 10% sodium fluorescein (Na-Fluor, intraperitoneal ad-
ministration) and monitoring fluorescence in spinal ho-
mogenates after 10 minutes.
For histology and immunofluorescence, cervical and
thoracic cord segments were snap frozen and sectioned
(10 μm) at peak disease scores, determined empirically
for each mouse as the fifth day after initial disease signs
(score >0). Tissue was stained with hematoxylin and
eosin (H&E) to detect CNS inflammatory infiltrates, or
solochrome cyanin to assess myelination, and qualitative
assessment of each parameter was performed as de-
scribed previously [16]. All assessments were made by a
blinded observer. For immunohistochemistry, primary
antibodies were rat anti-CD11b (EMD-Millipore, Biller-
ica, MA, USA), rat anti-CD4 (BD Biosciences, San
Diego, CA, USA), rabbit anti-ROR-γT (Abcam, Cam-
bridge, MA, USA) and mouse anti-T-bet (Abcam). Pri-
mary antibodies were applied overnight at 4°C.
Secondary antibodies were either Alexa Fluor 488 or 560
conjugates (Life Technologies, Carlsbad, CA, USA).
Non-parametric two-tailed Mann–Whitney tests were
used to analyze the differences in EAE neurological
signs (two groups). Kruskal-Wallis non-parametric ana-
lysis of variance (ANOVA) with Dunn’s multiple com-
parisons test was used for qualitative assessment of
clinical scoring with more than two groups. For all other
comparisons, one-way ANOVA followed by Student
Newman-Keuls multiple comparison test was used.
Results
Silencing PARP-2 protects neurological function and
reduces blood-spine barrier permeability in mouse EAE
EAE was induced in PARP-2 null mice and wild-type litter-
mate C57Bl/6 controls. Body mass and neurological signs
of disease were monitored for 35 days after the second
MOG35-55 immunization. Figure 1A shows the temporal
disease profile for C57Bl/6 (n = 9) and PARP-2 null mice
(n = 6). PARP-2 deletion reduced the 35 day total disease
burden (aggregate daily score per 35 EAE days) from 4.8 ±
1.5 to 2.6 ± 1.0 and the peak neurological severity score
from 9.6 ± 1.1 to 6.9 ± 2.2 (Figure 1B). PARP-2 deletion
also significantly increased the number of days required to
reach disease peak from 8.7 ± 3.5 days to 13.4 ± 2.7 days
after the second immunization (Figure 1C).
Blood-spine barrier (BSB) permeability was assessed im-
mediately following large weight loss (1.89 ± 0.66 g, n =
13) corresponding to peak transient BSB permeability
[18]. Following intraperitoneal Na-Fluor administration
(10 minutes), spinal fluorescence increased tenfold in EAE
mice (n = 4) compared to vehicle-treated (sham, n = 3)
controls (Figure 1D). BSB permeability was also signifi-
cantly enhanced by PARP-2 null EAE mice (n = 4), com-
pared to the PARP-2 null sham group (n = 4), however,
the magnitude of this enhancement was considerably
smaller (3.7-fold) than observed in wild-type mice.
PARP-2 deletion reduces spinal inflammatory cell
infiltration and demyelination in EAE
Mice were sacrificed at peak EAE score, designated as day
5 after each individual animal displayed a neurological score
greater than 0, and cervical and thoracic spinal sections
were stained with H&E. Wild-type EAE mice exhibited ex-
tensive perivascular parenchymal cell infiltration, relative to
sham animals (Figure 2A,B), which was reduced by PARP-2
deletion (Figure 2C). Quantification in Figure 2D shows
that central infiltration in wild-type mice (n = 7) is statisti-
cally reduced by the parp-2−/− genotype (n = 4).
We next investigated whether there was proinflammatory
T lymphocyte infiltration. Parenchymal CD4+ cell counts
per mm2 increased from 36.1 ± 12.8 to 400.1 ± 63.0 in
spinal cord sections of EAE mice (n = 7), relative to sham
controls (n = 3). PARP-2 deletion significantly reduced EAE
CD4+ counts to 146.7 ± 12.8 (n = 4; Figure 3A-C). To de-
termine effects of PARP-2 on proinflammatory Th1 and
Th17 T helper cell phenotypes, coimmunofluorescence ex-
periments were performed for CD4 and either T-bet (Th1)
[19] or ROR-γT (Th17) [20]. EAE increased the number of
CD4+/T-bet+ cells from 3.9 ± 1.6 in sham cords (n = 3) to
94.8 ± 14.6 in EAE (n = 7). Elimination of PARP-2 reduced
this to 21.7 ± 2.8 cell/mm2 (n = 4; Figure 3D). Similarly,
EAE increased CD4+/ROR-γT+ cell counts from 1.6 ± 0.8
in sham controls to 43.2 ± 6.9 in EAE in a manner
dependent on PARP-2, as deletion of PARP-2 reduced EAE
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Figure 1 Deletion of poly(ADP-ribose) polymerase 2 (PARP-2) protects neurological function and blood-spine barrier integrity in
experimental autoimmune encephalomyelitis (EAE) mice. (A) PARP-2 null and littermate C57Bl/6 mice were immunized with myelin
oligodendrocyte glycoprotein (MOG)35–55 and neurological signs of EAE were scored for 35 days. (A) Daily neurological scoring profile for wild-type
and PARP-2 null EAE mice. (B) Total disease burden (summed score/35 days) and peak neurological score were significantly reduced by PARP-2
deletion. (C) The number of days required to reach first peak disease score was significantly increased by PARP-2 deletion. (D) Spinal:serum
fluorescence was measured following sodium fluorescein (Na-Fluor) administration intraperitoneally just prior to peak disease neurological score. The
magnitude of the EAE-induced ratio increase was significantly less in PARP-2 mice than in wild-type animals. Values are expressed as mean ± SEM
(n = 6 to 9). (B,C) *P <0.05, using non-parametric two-tailed Mann–Whitney test. (D) ***P <0.001 compared to respective sham control, †P <0.001 as
indicated using one-way analysis of variance (ANOVA) followed by Student Newman-Keuls multiple comparisons test.
Figure 2 Poly(ADP-ribose) polymerase 2 (PARP-2) deletion reduces spinal inflammation. (A-C) Peak experimental autoimmune
encephalomyelitis (EAE) disease ((B) wild-type and (C) PARP-2 null) and sham control (A) spinal cords were subjected to hematoxylin and eosin
staining. Wild-type EAE cords have substantial cellular infiltration to the parenchyma (B) while the sham control (A) and PARP-2 EAE cords (C)
have minimal visible infiltration. Results are quantified in (D). Arrows point to perivascular foci of inflammatory infiltration. Scale bars are 200 μm
(top row, (A-C)) and 25 μm (bottom row, (A-C)); bottom row in (A-C) represents magnification of top row framed areas. Values are mean ± SEM
(n = 3 to 7). Results in (D) were analyzed using Kruskal-Wallis non-parametric analysis of variance (ANOVA) with Dunn’s multiple comparisons test.
**P <0.01 compared to sham; *P <0.05 compared to wild-type EAE group; not significant = P >0.05.
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counts to 14.0 ± 2.7 (Figure 3E-H). Salutary effects of
PARP-2 deletion on spinal microglial/macrophage CD11b
accumulation in EAE were also observed. Spinal regions
with H&E stain-verified inflammation exhibited widespread
CD11b+ immunoreactivity (IR) in EAE (Figure 4A, B) that
was PARP-2 dependent (Figure 4C, D).
Multifocal areas of reduced solochrome cyanin inten-
sity revealed widespread, diffuse demyelination in wild-
Figure 3 Poly(ADP-ribose) polymerase 2 (PARP-2) deletion reduces Th1 and Th17 T helper cell infiltration in experimental autoimmune
encephalomyelitis (EAE) mice spinal cords. Sham control and peak EAE spinal cords from wild-type and PARP-2 null mice were subjected to
coimmunofluorescence staining using antibodies for CD4 and T-bet (A-D) or CD4 and ROR-γT (E-H). Widespread CD4+ immunoreactivity (IR) was
observed in wild-type EAE spinal sections (B), approximately 24% of which was also T-bet+. The inset shows a magnified image of the area directly to
the right of the asterisk symbol (*) and illustrates cellular colocalization (yellow). (B) Representative image of reduced CD4+ and CD4+/T-bet+ infiltration
in PARP-2 null EAE cords. (C,D) Quantifications of CD4+ and CD4+/T-bet+ cell counts and indicate a significant reduction of each with elimination of
PARP-2. In (E), 12% of CD+ cells were also ROR-γT+. The inset in (E) shows a magnified image of the area directly to the left of the asterisk symbol (*).
(F) Representative image of reduced CD4+ and CD4+/ROR-γT+ infiltration in PARP-2 null EAE cords. (G,H) Quantifications of CD4+ and CD4+/ROR-γT+
cell counts and indicate a significant reduction of each with elimination of PARP-2. Results in (C,D,G,H) are expressed as means ± SEM and were
analyzed using one-way analysis of variance (ANOVA) with the Student Newman-Keuls multiple comparison test. **P <0.01 compared to sham;
*P <0.05 compared to wild-type EAE; not significant = P >0.05. Scale bars are 25 μm.
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type EAE mice (Figure 4E, F) that was significantly re-
duced in PARP-2 null EAE mice (Figure 4G, H). These
results support a role for PARP-2 in EAE-induced spinal
demyelination in mice.
Discussion
We addressed the role of PARP-2 in EAE using parp-2−/−
mice. Embryonic deletion of PARP-2 protected EAE mice
from neuroinflammation and neurological dysfunction.
Overall, parp-2−/− mice had significantly lower total dis-
ease burden over the 35 day period studied, compared to
wild-type C57Bl/6 controls. Peak EAE neurological scores
were also significantly reduced by eliminating PARP-2. In
practical terms, this peak protection means that hindlimb
paralysis and tail/forelimb weakness observed in wild-type
EAE mice were prevented in parp-2−/− mice, which expe-
rienced average maximal scores corresponding to hind-
limb weakness but no paralysis or tail and forelimb effects.
In addition, while we found a discernable peak EAE score
in parp-2−/− mice, the peak was shifted temporally further
away from EAE induction, compared to wild-type mice,
representing a 50% delay in EAE peak effect. We also eval-
uated BSB permeability and series of markers for EAE
neuroinflammation. The parp-2−/− genotype significantly
reduced EAE-induced BSB permeability and spinal distri-
butions of CD4+/T-bet+, CD4+/ROR-γT+, and CD11b+ in-
flammatory infiltrates, as well as demyelination in the
cervical and thoracic spinal cord. Taken together, these
data demonstrate that embryonic deletion of PARP-2 pro-
tects nerve myelin and motor performance while reducing
neuroinflammation associated with EAE.
Our observation that PARP-2 deletion is protective in
EAE raises the possibility that PARP inhibitors shown pre-
viously to have beneficial effects in EAE are effective at
least partially by interfering with the PARP-2 isoform. In
agreement, PJ34 [11], 6(5H)-phenanthridinone (PHE) [10]
and 5-aminoisoquinolinone (5-AIQ) [13] improved EAE
outcomes and all compete for the NAD+ binding site of
Figure 4 Poly(ADP-ribose) polymerase 2 (PARP-2) contributes to macrophage accumulation and spinal demyelination in experimental
autoimmune encephalomyelitis (EAE). CD11b immunofluorescence was used to detect macrophage/microglial cells activated by EAE. (B)
Representative images illustrating elevated CD11b+ immunoreactivity in wild-type EAE spinal sections compared with sham sections (A). PARP-2
deletion reduced CD11b IR (C). Results were quantified in (D). Values are mean ± SEM (n = 3 to 7) and were analyzed using one-way analysis of
variance (ANOVA) with the Student Newman-Keuls multiple comparison test. **P <0.01 compared to sham; ††P <0.01 compared to wild-type EAE;
not significant = P >0.05. Scale bars are 200 μm (top row, A-C) and 25 μm (bottom row, (A-C)). Bottom row represents magnification of framed
areas in the top row. Demyelination was assessed in peak disease EAE mice by staining with solochrome cyanin. Wild-type sham spinal cord
white matter is thoroughly myelinated, as indicated by deep blue staining (E). Wild-type EAE spinal cords exhibit extensive areas of demyelination
(F). EAE in PARP-2 null spinal cords produced only a low degree of demyelination (G) relative to wild-type controls. Results are quantified in (H)
and show a significant reduction in demyelination of PARP-2 null cords compared to wild-type cords in EAE. Scale bars are 200 μm. Values are
mean ± SEM (n = 3 to 6). Results in (H) were analyzed using non-parametric two-tailed Mann–Whitney test. *P <0.05 compared to wild-type
EAE group.
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both PARP-1 and PARP-2 [21-23], and we (data not
shown) and others [14] found that PARP-1 deletion is not
protective but rather enhances peak disease severity. How-
ever, PARP-1 deletion reduced neuroinflammation and
improved EAE outcome in another EAE model [13], mak-
ing categorical conclusions about the relative roles of
PARP-1 and PARP-2 in EAE difficult at this point. It
should be noted that embryonic deletion of PARP
isoforms prior to EAE could have different effects on EAE
outcomes than adult pharmacological or genetic loss of
function. For example, parp-1−/− mice have higher num-
bers of regulatory and EAE-activated CD4+/CD8+ T lym-
phocytes compared with wild-type animals [14,24] and
parp-2−/− mice exhibit reduced thymus size, cellularity
and numbers of peripheral T cell precursor thymocytes
[25]. In both of these cases, there could be a phenotypic
predisposition to a different immune response prior to
EAE induction that would not be present in wild-type ani-
mals. Further work employing models in which PARP
isoforms can be selectively inhibited or deleted just prior
to or during EAE (conditional knockouts) are required to
precisely delineate the neuroinflammatory roles of PARP-
1 and PARP-2, and to determine the potential usefulness
of these isoforms as therapeutic targets in adult EAE.
Conclusions
The current study implicates PARP-2 in neuroin-
flammation and neurological signs of EAE for the first time.
Identification of a selective role for PARP-2 in EAE pro-
gression establishes a novel therapeutic target of interest for
neuroinflammation and MS.
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